---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003005"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:28:13.252433+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned

## Summary
- Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.
- Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.
- CTX-8371 cohort expansions in TNBC, NSCLC, HL initiated; dose-escalation data at ASCO 2026 poster.
- CTX-10726 Phase 1 study initiated; initial clinical data expected in Q4 2026.
- Cash and marketable securities $195M at Q1 2026; net loss $18.3M ($0.10/share); cash runway into 2028.

## SEC filing metadata
- accession: 0001171843-26-003005
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/0001171843-26-003005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/f8k_050426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003005
- JSON: https://secwatch.observer/filing/0001171843-26-003005.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003005.txt

## Source-grounded claims
- claim_id: 1e9240900bcb13580afd8a3528ae9e6eac4445a3
  claim: Compass Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $195 million in cash and marketable securities.
  evidence_excerpt: The Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) has also been initiated in the post-checkpoint inhibitor setting, with initial data expected [Q4 2026]. $195 million in cash and marketable securities at Q1 2026, which is expected to fund operations into 2028. BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/0001171843-26-003005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.